109
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis

, , , , , , , & show all
Pages 593-607 | Published online: 04 Feb 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Asad Majeed Khan, Muhammad Hanif, Nadeem Irfan Bukhari, Rahat Shamim, Fatima Rasool, Sumaira Rasul & Sana Shafique. (2020) Artificial Neural Network (ANN) Approach to Predict an Optimized pH-Dependent Mesalamine Matrix Tablet. Drug Design, Development and Therapy 14, pages 2435-2448.
Read now

Articles from other publishers (8)

Nicholas Michael Croft, Bartosz Korczowski, Jarosław Kierkuś, Beatriz Caballero & Manoj Kumar Thakur. (2023) Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind study. eClinicalMedicine 65, pages 102232.
Crossref
Junrong Li, Fangmei Ling, Di Guo, Jinfang Zhao, Ling Cheng, Yidong Chen, Mingyang Xu & Liangru Zhu. (2022) The efficacy of mesalazine on nonspecific terminal ileal ulcers: A randomized controlled trial. Frontiers in Pharmacology 13.
Crossref
Yuichiro Ohtaki, Kan Uchiyama, Hirotaka Kamiya, Eri Moriizumi, Moe Yamada, Yuma Aoki, Toshimune Watanabe, Sachie Kiryu, Shizuka Suzuki, Yoshihiro Matsumoto, Zensho Ito, Toshifumi Ohkusa, Shigeo Koido & Masayuki Saruta. (2022) The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis. BMC Gastroenterology 22:1.
Crossref
Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kirandeep Kaur, Rajeev Khosla, Ajay Kumar, Ramit Mahajan, S. P. Misra, Kiran Peddi, Shivaram Prasad Singh & Arshdeep Singh. (2020) Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intestinal Research 18:4, pages 355-378.
Crossref
Palika DattaKathleen Rewers-FelkinsRaja Reddy KallemTeresa BakerThomas W. Hale. (2019) Determination of Mesalamine levels in Human Milk as a Function of Dose. Breastfeeding Medicine 14:2, pages 98-101.
Crossref
Amy Hemperly, William J Sandborn & Niels Vande Casteele. (2018) Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 24:12, pages 2527-2542.
Crossref
Dan Turner, Frank M. Ruemmele, Esther Orlanski‐Meyer, Anne M. Griffiths, Javier Martin de Carpi, Jiri Bronsky, Gabor Veres, Marina Aloi, Caterina Strisciuglio, Christian P. Braegger, Amit Assa, Claudio Romano, Séamus Hussey, Michael Stanton, Mikko Pakarinen, Lissy de Ridder, Konstantinos Katsanos, Nick Croft, Victor Navas‐López, David C. Wilson, Sally Lawrence & Richard K. Russell. (2018) Management of Paediatric Ulcerative Colitis, Part 1. Journal of Pediatric Gastroenterology and Nutrition 67:2, pages 257-291.
Crossref
Alex Yu, Jason R. Baker, Ann F. Fioritto, Ying Wang, Ruijuan Luo, Siwei Li, Bo Wen, Michael Bly, Yasuhiro Tsume, Mark J. Koenigsknecht, Xinyuan Zhang, Robert Lionberger, Gordon L. Amidon, William L. Hasler & Duxin Sun. (2016) Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract . Molecular Pharmaceutics 14:2, pages 345-358.
Crossref